RxDoctor Payments Data

Andrew Chandler, DO

Family Medicine · Greensburg, INNPI 1457516809

Payments from drug & device makers

$10,354in general payments, 2019–2025

Across 625 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Lilly USA, LLC$1K
  • Vanda Pharmaceuticals Inc.$750
  • AstraZeneca$465
  • Novo Nordisk$408
  • plus $4K from 33 others

What the payments were for

  • Consulting fees$1,20012%
  • Travel & lodging$1031%
  • Food & beverage$8,90386%
  • Education$1491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,354 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$49,701
Medicare patients
73
Services billed
680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin47$77,654
MounjaroTirzepatide67$71,332
TrulicityDulaglutide31$35,737
XareltoRivaroxaban21$31,102
EliquisApixaban30$28,008
VraylarCariprazine Hcl17$25,238
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$24,642
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$21,642
OzempicSemaglutide13$19,726
QuliptaAtogepant11$13,989
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$6,877
Varenicline Tartrate22$6,782
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$6,648
LinzessLinaclotide12$6,242
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen344$5,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,092$107,06998 claims
Boehringer IngelheimJardiance$197$77,65447 claims
AbbVieVraylar, Qulipta, Linzess, Synthroid$2,628$47,31253 claims
Johnson & JohnsonXarelto$137$31,10221 claims
GSKTrelegy Ellipta, Anoro Ellipta$213$28,51932 claims
PfizerEliquis$392$28,00830 claims
AstraZenecaBreztri Aerosphere$465$24,64234 claims
Novo NordiskOzempic$408$19,72613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Greensburg

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →